Ads
related to: biofilm infection treatment- Biofilm Phase-2
Advanced Biofilms 60 veggie caps
by Priority One Vitamins
- Biocidin®
Potent, Broad-Spectrum Liquid Caps
by Biocidin Botanicals
- Boluoke® RNA Supplement
Shop Boluoke Lumbrokinase Today
30, 60, 120 caps avaliable
- Biofilm Defense®
Biofilm Dissolver - 60 caps
by Kirkman Labs
- Biofilm Phase-2
Search results
Results from the WOW.Com Content Network
The different steps at which phages may disrupt biofilm formation. The biofilm surrounding the bacteria would inhibit the ability of antibiotics to reach bacteria, but may have less impact on the phages. Phage therapy is being used to great effect in the treatment of biofilm infections, especially Pseudomonas aeruginosa and Staphylococcus aureus.
Biofilm formation of P. aeruginosa, along with other bacteria, is found in 90% of chronic wound infections, which leads to poor healing and high cost of treatment estimated at more than US$25 billion every year in the United States. [113]
Biofilms serve to protect these bacteria from adverse environmental factors, including host immune system components in addition to antibiotics. P. aeruginosa can cause nosocomial infections and is considered a model organism for the study of antibiotic-resistant bacteria.
Because biofilms protect the bacteria, they are often more resistant to traditional antimicrobial treatments, making them a serious health risk. [1] For example, there are more than one million cases of catheter-associated urinary tract infections (CAUTI) reported each year, many of which can be attributed to bacterial biofilms. [2]
While examining the role of biofilms in multiple otolaryngologic infections, Ehrlich concluded that understanding their physiology would be key to the formulation of effective treatment strategies [21] [22] as biofilm bacteria are resistant to classical antimicrobial therapies. With this focus on developing methods for ameliorating chronic ...
Nitroxoline is an antibiotic [1] that has been in use in Europe for about fifty years, and has proven to be very effective at combating biofilm infections. Nitroxoline was shown to cause a decrease in the biofilm density of P. aeruginosa infections, which would allow access to the infection by the immune system in vivo. [2]
Although S. epidermidis is not usually pathogenic, patients with compromised immune systems are at risk of developing infection. These infections are generally hospital-acquired. [4] S. epidermidis is a particular concern for people with catheters or other surgical implants because it is known to form biofilms that grow on these devices. [5]
Persister cells are highly enriched in biofilms, and this makes biofilm-related diseases difficult to treat. Examples are chronic infections of implanted medical devices such as catheters and artificial joints, urinary tract infections, middle ear infections and fatal lung disease. [13]
Ads
related to: biofilm infection treatment